PVCT Provectus Biopharmaceuticals - adding to your Occular point, rmgillis - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  5743 of 5830  at  10/30/2020 10:24:43 AM  by

leave_the_gun


adding to your Occular point, rmgillis


  From the Delcath announcement:
 
"We found the presence of a liver metastasis with diameter ≥ 3 cm and elevated LDH level to be poor prognostic factors for OS"
 
Our trial had 4 patient >3cm and 46% with elevated LDH.
 
"Additionally, we excluded patients with elevated LDH levels at baseline, and it has been demonstrated that an elevated LDH is associated with a poor OS in patients with metastatic ocular melanoma".
 
In our study, 8 out of the 13 patients had elevated LDH levels. The Delcath study excluded these patients altogether. 
 
But the Delcath study is full of trial designs that specifically set things up in their favor in order to overinflated their result numbers.
 
Just another headline hit-job by the hypocrite that analyzes every word of the PVCT announcements in order to diminish the results, yet can't even do basic reading when trying to write headlines for others.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
5744 Re: adding to your Occular point, rmgillis Take_The_Canolis 2 10/30/2020 11:46:22 AM








Financial Market Data provided by
.
Loading...